The potential of TFPI2 as a tumor suppressor has been suggested in a variety of studies, as TFPI2 has been shown to inhibit extracellular matrix degradation in various malignancies, including pancreatic cancer 7, 8, prostate cancer 9, breast cancer 10, gastric cancer 11, glioblastoma 12, and HCC 13. This evidence concerns the gene TFPI2 and prostate carcinoma.